Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

13.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
125
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

3.2K
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of the genotypic and phenotypic spectrum of TCF7L2-related neurodevelopmental disorder (TRND).

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Synovial biopsy and tissue sampling in the management of RA.

Rheumatology (Oxford, England)·2026
Same author

multiDEGGs: Single or Multiomic Differential Network Analysis for Biomarker Discovery and Feature Engineering for Predictive Modeling.

Computational and structural biotechnology journal·2026
Same author

IDEA-FAST clinical study protocol: Identifying digital end-points of fatigue, sleep quality and daytime sleepiness in N = 2000.

Digital health·2026
Same author

Ultrasound-Guided Synovial Biopsy Can Be Effectively and Safely Performed in Different Clinical Settings Favouring a Widespread Application of Precision Medicine in Rheumatoid Arthritis: A Post-hoc Analysis of Three Clinical Trials.

Journal of clinical medicine·2026
Same author

GREM1 acts in leptin receptor-expressing skeletal cells to mediate peri-implant fibrosis.

Nature communications·2026

Related Experiment Video

Updated: Jun 22, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

119

Another Notch in the Belt of Rheumatoid Arthritis.

Stephanie R Zack1, Osama Alzoubi1, Neha Satoeya1

  • 1Jesse Brown VA Medical Center and The University of Illinois at Chicago, Chicago, Illinois.

Arthritis & Rheumatology (Hoboken, N.J.)
|July 4, 2024
PubMed
Summary

The Notch signaling pathway is active in early rheumatoid arthritis (RA) but not in later stages. Tumor necrosis factor (TNF) influences Notch ligands, and while some drugs reduce Notch expression, inhibitors have failed, suggesting new strategies are needed.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

68
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
06:31

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

2.1K

Related Experiment Videos

Last Updated: Jun 22, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

119
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

68
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
06:31

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

2.1K

Area of Science:

  • Rheumatology
  • Immunology
  • Cell Biology

Background:

  • The Notch signaling pathway plays a crucial role in cell communication and development.
  • Dysregulation of Notch signaling has been implicated in various inflammatory diseases, including rheumatoid arthritis (RA).
  • Understanding Notch pathway involvement in RA pathogenesis is essential for developing targeted therapies.

Purpose of the Study:

  • To investigate the role and regulation of the Notch signaling pathway in rheumatoid arthritis (RA) synovial tissues (ST).
  • To identify key inducers and modulators of Notch expression in RA.
  • To evaluate the efficacy of current RA treatments on Notch pathway components.

Main Methods:

  • Analysis of Notch ligand and receptor expression in RA synovial tissues (ST) and normal tissues using immunohistochemistry and Power Doppler ultrasound.
  • In vitro studies involving macrophages (MΦs), fibroblast-like synoviocytes (FLS), and endothelial cells stimulated with tumor necrosis factor (TNF).
  • Assessment of Notch pathway modulation by disease-modifying antirheumatic drugs (DMARDs) and other biologics in co-cultures and organoid models.

Main Results:

  • Notch ligands and receptors are enriched in RA ST, particularly on MΦs, FLS, and endothelial cells, and are associated with early active RA and neovascularization.
  • Toll-like receptors and TNF induce Notch expression in RA cells; JAG1 and DLL4 are key inducible ligands.
  • Anti-TNF therapy downregulates Notch ligands in myeloid cells; specific DMARDs reduce JAG1 and Notch3 expression, but Methotrexate, IL-6R, and B cell blockers are ineffective.
  • NF-κB, MAPK, and AKT pathways are involved in Notch signaling, while JAK/STATs are not.

Conclusions:

  • The Notch signaling pathway is implicated in early active RA, especially during neovascularization, but not in the erosive stage.
  • TNF is a central regulator of Notch ligands in RA, and its inhibition impacts Notch expression.
  • Current therapeutic strategies targeting Notch signaling have limitations, necessitating the exploration of alternative approaches for RA treatment.